JP2012513391A - 修飾ポリエチレングリコール中間体を得るための合成法 - Google Patents

修飾ポリエチレングリコール中間体を得るための合成法 Download PDF

Info

Publication number
JP2012513391A
JP2012513391A JP2011542223A JP2011542223A JP2012513391A JP 2012513391 A JP2012513391 A JP 2012513391A JP 2011542223 A JP2011542223 A JP 2011542223A JP 2011542223 A JP2011542223 A JP 2011542223A JP 2012513391 A JP2012513391 A JP 2012513391A
Authority
JP
Japan
Prior art keywords
mixture
linker
formula
case
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011542223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012513391A5 (enExample
Inventor
エンゲル，トルグリム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of JP2012513391A publication Critical patent/JP2012513391A/ja
Publication of JP2012513391A5 publication Critical patent/JP2012513391A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3324—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof cyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33331—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group
    • C08G65/33337—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group cyclic
    • C08G65/33341—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group cyclic aromatic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyethers (AREA)
JP2011542223A 2008-12-22 2009-12-07 修飾ポリエチレングリコール中間体を得るための合成法 Pending JP2012513391A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13968908P 2008-12-22 2008-12-22
US61/139,689 2008-12-22
PCT/US2009/066917 WO2010074935A1 (en) 2008-12-22 2009-12-07 Synthesis of obtaining modified polyethylene glycol intermediates

Publications (2)

Publication Number Publication Date
JP2012513391A true JP2012513391A (ja) 2012-06-14
JP2012513391A5 JP2012513391A5 (enExample) 2012-12-27

Family

ID=41818624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011542223A Pending JP2012513391A (ja) 2008-12-22 2009-12-07 修飾ポリエチレングリコール中間体を得るための合成法

Country Status (5)

Country Link
US (1) US8536375B2 (enExample)
EP (1) EP2370501A1 (enExample)
JP (1) JP2012513391A (enExample)
CN (1) CN102325823B (enExample)
WO (1) WO2010074935A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020008540A2 (pt) * 2017-11-06 2020-10-06 Hanmi Fine Chemical Co., Ltd. derivado de polietilenoglicol e método de preparação deste
CA3111878A1 (en) 2018-09-07 2020-03-12 Merck Patent Gmbh 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) * 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
ES2199935T3 (es) * 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
EP1664316B1 (en) * 2003-09-15 2012-08-29 Protiva Biotherapeutics Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
US8415510B2 (en) * 2008-02-28 2013-04-09 Ge Healthcare Limited Synthesis of a PEG-6 moiety from commercial low-cost chemicals

Also Published As

Publication number Publication date
CN102325823A (zh) 2012-01-18
CN102325823B (zh) 2014-02-26
EP2370501A1 (en) 2011-10-05
US8536375B2 (en) 2013-09-17
US20120004423A1 (en) 2012-01-05
WO2010074935A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
JP4877225B2 (ja) ポリオキシアルキレン誘導体
JP6334399B2 (ja) 自己組織化ペプチド誘導体の製造方法
AU2012301793A1 (en) Branched discrette PEG constructs
JP5399422B2 (ja) 市販の安価な化学薬品からのｐｅｇ−６成分の合成
WO2022106629A1 (en) Synthesis of prostate specific membrane antigen (psma) ligands
JP2012513391A (ja) 修飾ポリエチレングリコール中間体を得るための合成法
TW200906819A (en) Method for preparing Fmoc-based hydrolysable linkers
US20240018099A1 (en) Synthesis of prostate specific membrane antigen (psma) ligands
US9944750B2 (en) Polyethylene glycol substituted acyl borates
JP3418693B2 (ja) ポリ−ε−置換−Ｌ−リジンのＤ−ガラクトピラノシル−グルコン酸誘導体
JP2021532196A (ja) ペクチン−ドキソルビシン共役化合物及びその調製方法と用途
US12454526B2 (en) Method for producing pyrrole-imidazole (poly)amide
JPH0790080A (ja) ポリ−ε−置換−Ｌ−リジンのＤ−ガラクトピラノシル−グルコン酸誘導体
US20240010623A1 (en) Synthesis of prostate specific membrane antigen (psma) ligands
KR100551096B1 (ko) 신규한 와이-폴리에틸렌글리콜 유도체 및 그의 제조방법
JP5982720B2 (ja) 高分子固体状支持体を用いたヒスチジル−プロリンアミド誘導体の製造方法
WO2025193170A1 (en) A polymer, a method of preparing the polymer and its uses thereof
CN118754934A (zh) 一种用于制备药物偶联物的毒素衍生物
JP2001323059A (ja) ポリペプチド誘導体および核酸運搬体
WO2008105759A1 (en) Methods for synthesis of modified peptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140310

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140409

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140509

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140516

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141028